Cara Therapeutics, Inc. (CARA)
CARAPrice: $5.32
Fair Value: 🔒
🔒score
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that ... more
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing ... more
Description
Shares
| Market Cap | $8.11M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Christopher A. Posner |
| IPO Date | 2014-01-31 | CAGR | — |
| Employees | 10 | Website | www.caratherapeutics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CARA chart loading...
Fundamentals
Technicals
| Enterprise Value | $1.30B | P/E Ratio | -0.11 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 5.73 | P/B Ratio | 1.01 |
| P/CF Ratio | -1.05 | P/FCF Ratio | -1.19 |
| EPS | $-46.59 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -40.16% | Gross Margin | 0.98% |
| Operating Margin | -3.58% | Profit Margin | -3.18% |
| ROE | 1.43% | ROA | -0.48% |
| ROCE | -0.71% | Current Ratio | 4.04 |
| Quick Ratio | 4.04 | Cash Ratio | 1.93 |
| Debt/Equity | 0.01 | Interest Coverage | -3.16 |
| Altman Z Score | -3.51 | Piotroski Score | 2 |